Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

In recent months, the Delaware Court of Chancery has decided four significant cases regarding merger agreement earnout provisions. Most notably, ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

The initial program, dubbed Geneious Luma, aims to focus on monoclonal and multispecific antibodies. It will take the ability ...

Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathyAdditional oral presentation ...

The first in a series of Dotmatics Luma Multimodal R&D Solutions. Geneious has been seamlessly composed into Luma showcasing cross-therapeutic capabilities within a unified platfo ...

New York, October 22, 2024 – Nodenza Venture Partners (“Nodenza”), today announces its investment in Trellis Bioscience (“Trellis”), a clinical-stage company focused on discovering and developing ...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner ...

Cantor Fitzgerald reissued their overweight rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a report published on ...